CA2444347A1 - Method for treating gout and binding uric acid - Google Patents

Method for treating gout and binding uric acid Download PDF

Info

Publication number
CA2444347A1
CA2444347A1 CA002444347A CA2444347A CA2444347A1 CA 2444347 A1 CA2444347 A1 CA 2444347A1 CA 002444347 A CA002444347 A CA 002444347A CA 2444347 A CA2444347 A CA 2444347A CA 2444347 A1 CA2444347 A1 CA 2444347A1
Authority
CA
Canada
Prior art keywords
polymer
uric acid
solid
cross
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002444347A
Other languages
English (en)
French (fr)
Inventor
Stephen Randall Holmes-Farley
Steven K. Burke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2444347A1 publication Critical patent/CA2444347A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Dental Preparations (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002444347A 2001-04-18 2002-04-10 Method for treating gout and binding uric acid Abandoned CA2444347A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28444501P 2001-04-18 2001-04-18
US60/284,445 2001-04-18
US30556701P 2001-07-13 2001-07-13
US60/305,567 2001-07-13
PCT/US2002/011492 WO2002085381A1 (en) 2001-04-18 2002-04-10 Method for treating gout and binding uric acid

Publications (1)

Publication Number Publication Date
CA2444347A1 true CA2444347A1 (en) 2002-10-31

Family

ID=26962624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002444347A Abandoned CA2444347A1 (en) 2001-04-18 2002-04-10 Method for treating gout and binding uric acid

Country Status (9)

Country Link
US (2) US20030039627A1 (enExample)
EP (1) EP1416942B1 (enExample)
JP (1) JP2004528332A (enExample)
AT (1) ATE380553T1 (enExample)
BR (1) BR0209133A (enExample)
CA (1) CA2444347A1 (enExample)
DE (1) DE60224052T2 (enExample)
MX (1) MXPA03009571A (enExample)
WO (1) WO2002085381A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
AU2003282867A1 (en) * 2002-10-22 2004-05-13 Genzyme Corporation Amine polymers for promoting bone formation
WO2004099288A1 (en) * 2003-05-09 2004-11-18 Carlsberg A/S Polyethyleneimine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
WO2006072054A1 (en) * 2004-12-30 2006-07-06 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
CA2607953A1 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
JP2009507019A (ja) * 2005-09-02 2009-02-19 ジェンザイム・コーポレーション リン酸塩を除去する方法およびそれに使用される重合体
KR101547925B1 (ko) 2005-09-15 2015-08-27 젠자임 코포레이션 아민 중합체에 대한 샤셋 제형
WO2007056405A2 (en) * 2005-11-08 2007-05-18 Genzyme Corporation Magnesium-containing polymers for the treatment of hyperphosphatemia
JP2009536246A (ja) * 2006-05-05 2009-10-08 ゲンズイメ コーポレーション ホスフェート捕捉剤としてのアミン縮合重合体
EP2043627A2 (en) * 2006-07-05 2009-04-08 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
CA2658338A1 (en) * 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
WO2008042222A2 (en) 2006-09-29 2008-04-10 Genzyme Corporation Amide dendrimer compositions
CA2669935A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
WO2008076242A1 (en) * 2006-12-14 2008-06-26 Genzyme Corporation Amido-amine polymer compositions
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
EP2114376A1 (en) * 2007-02-23 2009-11-11 Genzyme Corporation Amine polymer compositions
WO2008109095A1 (en) * 2007-03-08 2008-09-12 Genzyme Corporation Sulfone polymer compositions
US20100166696A1 (en) * 2007-04-27 2010-07-01 Dhal Pradeep K Amido-amine dendrimer compositions
JP2011506449A (ja) * 2007-12-14 2011-03-03 ジェンザイム コーポレーション コーティング医薬組成物
WO2009154747A1 (en) * 2008-06-20 2009-12-23 Genzyme Corporation Pharmaceutical compositions
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
CN103298466B (zh) 2010-09-10 2015-11-25 武田制药美国有限公司 茶碱和非布索坦的联合治疗方法
ES2733493T3 (es) 2013-06-05 2019-11-29 Tricida Inc Polímeros de unión a protones para la administración oral
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
MA44875A (fr) 2016-05-06 2019-03-13 Tricida Inc Compositions pour le traitement de troubles acido-basiques
WO2018124264A1 (ja) 2016-12-28 2018-07-05 富士フイルム株式会社 窒素原子含有ポリマー又はその塩の乳化液、その製造方法、及び粒子の製造方法
JP6992084B2 (ja) 2017-10-16 2022-01-13 富士フイルム株式会社 高リン血症治療剤
WO2019090176A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
CN116018146A (zh) * 2021-08-24 2023-04-25 中美华世通生物医药科技(武汉)股份有限公司 用于治疗高尿酸血症的聚合物、组合物和方法
ES2980624T3 (es) * 2021-08-24 2024-10-02 Waterstone Pharmaceuticals Wuhan Co Ltd Polímeros, composiciones y métodos para tratar hiperuricemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271191A (en) * 1979-12-19 1981-06-02 Pierre Fabre S.A. Method of treating hyperuricemia and gout
DE3727082A1 (de) * 1987-08-14 1989-02-23 Goedecke Ag Pharmazeutische zubereitungen zur behandlung der urolithiasis
ATE361335T1 (de) * 1996-10-23 2007-05-15 Dow Global Technologies Inc Wasserlösliche polymere für die verminderung der absorption von diätetikem phosphat oder oxalat
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid

Also Published As

Publication number Publication date
JP2004528332A (ja) 2004-09-16
EP1416942A1 (en) 2004-05-12
DE60224052T2 (de) 2008-11-06
ATE380553T1 (de) 2007-12-15
US20080112918A1 (en) 2008-05-15
MXPA03009571A (es) 2004-02-12
US20030039627A1 (en) 2003-02-27
DE60224052D1 (de) 2008-01-24
BR0209133A (pt) 2004-06-15
EP1416942B1 (en) 2007-12-12
WO2002085381A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
EP1416942B1 (en) Amine polymers for treating gout and binding uric acid
US20020187120A1 (en) Method for treating gout and reducing serum uric acid
AU2002257145B2 (en) Method for lowering serum glucose
CA2349620C (en) Use of aliphatic polyamines for reducing oxalate
EP0996454B1 (en) Use of polyallylamine polymers for the manufacture of a medicament for treating hypercholesterolemia
US6566407B2 (en) Method for reducing oxalate
AU2002257145A1 (en) Method for lowering serum glucose
ZA200308063B (en) Method of lowering serum glucose.
US20020182168A1 (en) Method for reducing copper levels and treating copper toxicosis
US20020168333A1 (en) Method for improving vascular access in patients with vascular shunts
EP1923064B1 (en) Use of amine polymer for lowering serum glucose

Legal Events

Date Code Title Description
FZDE Discontinued